Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Issue 1 (2nd January 2019)

• Record Type: Journal Article
• Authors: Shima, Yoshihito; Kawaguchi, Yasushi; Kuwana, Masataka
• Is Part Of: Modern rheumatology. Volume 29:Issue 1(2019)
• Page Start: 134
• Page End: 139
• Publication Date: 2019-01-02
• Subjects: Systemic sclerosis -- tocilizumab -- IL-6 -- IL-13 -- CCL5; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2018.1452178
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: To evaluate the anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) as a treatment of systemic sclerosis (SSc), a randomised parallel group study was conducted, and compared their results and baseline cytokine/chemokine profiles. Methods: Patients were assigned to a TCZ add-on group (TCZ group, n = 7) and a conventional therapy group (Conv group, n = 6). TCZ (8 mg/kg/month) for 6 months, and the modified Rodnan total skin score (mRSS) were used to compare the efficacy. The association of medical history, baseline pulmonary function tests, blood cell counts, serum C-reactive protein (CRP) and 26 cytokines/chemokines and decrease in mRSS were analysed. Results: The mean change in mRSS was larger in the TCZ group (6.3) than in the Conv group (3.4), but the difference was not statistically significant because of high variance in the TCZ group. Patients with shorter disease histories and higher CRP had larger decreases in mRSS, and the decrease in mRSS was negatively correlated with IL-13 and C–C motif chemokine ligand (CCL)5. Conclusion: Although significant between-group differences were not observed, some patients had a decrease in mRSS. Short disease duration, high CRP, low IL-13 and low CCL5 may represent an SSc endotype responsive to TCZ therapy.